- Direction
- Improving
- Own history
- 75th
- Peers
- 43th
- Persistence
- EMERGING
· Pharmaceutical Preparations
RESEARCH SNAPSHOTBRISTOL MYERS SQUIBB CO's latest supported as-filed period reports revenue of $13.1B. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 326.09% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.63% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 31.99% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 6.93% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 20.69% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 68.28% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 39.1%; Operating cash flow decreased 33.8%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 30.8%; Operating cash flow decreased 13.4%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 7.5%; Capex / revenue moved 1 bp higher.
2 evidence-backed componentsCash & equivalents changed -39.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BMY · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000014272-26-000024SEC ↗8-KOct 29, 2026Period Oct 29, 20260000014272-26-000022SEC ↗4Oct 5, 2026Period Oct 2, 20260001995058-26-000007SEC ↗4Oct 2, 2026Period Sep 30, 20260001269070-26-000011SEC ↗4Oct 2, 2026Period Sep 30, 20260001688276-26-000010SEC ↗4Oct 2, 2026Period Sep 30, 20260001359067-26-000012SEC ↗4Oct 2, 2026Period Sep 30, 20260001418949-26-000010SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 2, 2026Filed Oct 5, 2026 | Gallman CariEVP, General Counsel | Option ExerciseDirect | 4,559 | $0 | $0 | Form 4 ↗ |
| Oct 2, 2026Filed Oct 5, 2026 | Gallman CariEVP, General Counsel | Tax WithholdingDirect | 2,332 | $61 | $142,602 | Form 4 ↗ |
| Oct 2, 2026Filed Oct 5, 2026 | Gallman CariEVP, General Counsel | Option ExerciseDirect | 4,559 | $0 | $0 | Form 4 ↗ |
| Sep 30, 2026Filed Oct 2, 2026 | Samuels Theodore R. IIDirector | Grant Or AwardDirect | 821.31 | $62 | $51,250 | Form 4 ↗ |
| Sep 30, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 18.10% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 1.06% · OPTIONAL
Cash & equivalents changed -30.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed -32.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed -33.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current long-term debt changed -82.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Short-term borrowings changed -78.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +74.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001323134-26-000024| YALE PHYLLIS RDirector |
| Grant Or AwardDirect |
| 560.9 |
| $62 |
| $35,000 |
| Form 4 ↗ |
| Sep 9, 2026Filed Sep 10, 2026 | Massacesi CristianEVP,Chief Med Offr,Head of Dev | Open Market SaleDirect | 6,249 | $65 | $403,498 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Short Bartie WendyEVP, Corporate Affairs | Option ExerciseDirect | 1,236 | $67 | $82,713 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Short Bartie WendyEVP, Corporate Affairs | Tax WithholdingDirect | 633 | $67 | $42,360 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Short Bartie WendyEVP, Corporate Affairs | Option ExerciseDirect | 1,236 | $0 | $0 | Form 4 ↗ |
| Aug 25, 2026Filed Aug 26, 2026 | Holzer Phil MSVP and Controller | Open Market SaleDirect | 500 | $68 | $33,750 | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Massacesi CristianEVP,Chief Med Offr,Head of Dev | Option ExerciseDirect | 51,172 | $0 | $0 | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Massacesi CristianEVP,Chief Med Offr,Head of Dev | Tax WithholdingDirect | 26,175 | $65 | $1.7M | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Massacesi CristianEVP,Chief Med Offr,Head of Dev | Option ExerciseDirect | 51,172 | $0 | $0 | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Gallman CariEVP, General Counsel | Option ExerciseDirect | 1,061 | $0 | $0 | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Gallman CariEVP, General Counsel | Tax WithholdingDirect | 543 | $65 | $35,463 | Form 4 ↗ |
| Aug 1, 2026Filed Aug 4, 2026 | Gallman CariEVP, General Counsel | Option ExerciseDirect | 1,061 | $0 | $0 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | YALE PHYLLIS RDirector | Grant Or AwardDirect | 607.43 | $58 | $35,000 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | Samuels Theodore R. IIDirector | Grant Or AwardDirect | 889.45 | $58 | $51,250 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | Rice Derica WDirector | Grant Or AwardDirect | 672.51 | $58 | $38,750 | Form 4 ↗ |
| Jun 30, 2026Filed Jul 2, 2026 | McMullen Michael R.Director | Grant Or AwardDirect | 607.43 | $58 | $35,000 | Form 4 ↗ |